Is no more post
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
who's Puma that sneaker company? i only care about the integrity and success of ENZC. Now if the IPF is not out this month - well who knows where the PPS will be in December, back down to the .002 range. jmo.
Mutat-yes he did state that the IPF will be available. But there is always a disclaimer at the bottom, theres are forward looking statements yada yada yada!!! I hope it does hit the market by months end. JMO.
thanks - looking for a nice step up pattern to form in the near future. (up stair case pattern). Happy Thanks Giving to all of us ENZC Turkeys!!!! I love my ENZC .
More to come as the ENZC train is just making a pit stop - no matter who post what on this thread none of it has any merit until the company tells what is and what is not. The ENZC games will continue until that time. JMO.
excellent - thanks for the update
I do not see the analogy - it's comparing apples to the auto industry - two way different industries. Just like Tesla adapts to the ever changing business environment around them ENZC is doing the same adapting to the ever changing business environment in the BIO Medical Science industry with new products and break throughs in the industry. I can see that but not your analogy a tesla to a scooter with missing wheel. JMO.
Timing101, sometimes less is more and in my opinion this is one if those times. thanks for your input.
Yeh I know I am a brain surgeon, Sunday couch
quarterback, LOL - JMO
SOOOOO much potential here just going to sit back and wait it out. Maybe get some more shares under 4 or even 3 cents again. Long and believe it is happening-when i do not know. JMO.
I did hear Peter was not giving up so easy on his lawsuit. I heard thru the grapevine he was looking to file in 3 other states - this was approx 4 weeks ago. I have not heard or seen anything more on it. Who knows with this delay - it is something they are not showing us- JMO.
Unaudited means nothing can be taken for being accurate on the filing correct? Need AUDITED FINS means MGT is still not showing it's shareholders the entire deck of cards - they are hiding something as UNAUDITED FINS is dragging out way too long. JMO.
Why is it still unaudited? Why? Why? Why?
The value is here - some just do not see it yet. Buy when there is blood in the streets-(meaning stock market). . This not yet a value stock but one day it will be. And yes I always buy value stocks cause they have value, currently ENZC does not hold that much monetary value - but the potential of ENZC gaining value is there big time. JMO
Thank you for the compliment even if it is a backhanded one. All the best to you. ENZC onward and upward.
ENZC was pumped and it was during the pandemic, people had free money to invest - it was the wild west out there in all markets the past 18months. Look at the dow , look at coin based markets, that is down as well. You need to take into account the economic environment at that time and the hype that was hyped on ENZC at that time - it was premature - now ENZC is ready to roll. JMO.
- that is just a chart and nothing else- wow great DD you got there. Keep up the fantastic work for all of us can make an educated decision on ENZC.
MamaDukes, great post and great read. thank you
One mans garbage is another's mans wealth!!! I disagree with your comments. But hey everyone has a opinion. JMO.
Charles and Dr Chandra make a great team and shares holders will reap the reward for sticking it out though the ups and downs. A great board of longs and DD. JMO.
If ENZC were going to fail it would have happened by now - failure s not happening here at ENZC. JMO
Dr Chandra will be nominated for the NOBEL PRIZE in Medicine in the next 1 -2 years. He is a genius just ELON MUSK - JMO.
Well, everyone is entitled to their opinion - but I disagree with ur post.
I disagree with ur post. JMO
they have three choices - the third is to do nothing. jmo.
Another very small fish like all of us in a very big bowl, JMO.
: ) YEP!!!!!
thanks JOE!!!!! We are getting closer step by step, inch by inch!!!
Timing101- I had no doubt the audit is coming - I just thought it would have been yesterday - looks like Monday the 21st. Great DD Timing101. thank you for confirming what Ralphie Jones tells me.
??????, ??????, ??????, ?????? ???? ?? ?? ?????!!!!
nope - it's over - caput!!! Nothing!!!!!
Research and Markets
Mon, 14 November 2022 at 4:28 am·4-min read
Company Logo
Company Logo
Dublin, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The "Biologics Outsourcing Global Market - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030. Major drivers for the biologics outsourcing market include increasing trend of outsourcing among the biopharma companies for gaining an economical access to advanced biologics development and manufacturing capacities and capabilities, advanced bioprocessing capabilities of bioservice providers, increasing approvals and adoption of biologics, increasing R&D spend of biopharma companies and escalating approvals and uptake of biosimilars.
Factors like emergence of next generation biotherapeutics, development of personalized and orphan indication therapies and the persistently escalating prevalence of chronic, communicable and autoimmune diseases are expected to boost the market growth. However, increasing focus on in-house biologics manufacturing, huge capital investments for capacity and capability development and compliance with stringent regulatory guidelines are restraining the market.
- ADVERTISEMENT -
This fast pacing biologic industry coupled with insufficient or lack of in house biologic development and manufacturing capabilities and capacities of biopharmaceutical companies has spurred these companies to outsource various phases of biologic development and manufacturing process to highly efficient service provider organizations. To tap this market of high growth potential as the advantageous first movers or to increase accessibility in this rapidly growing market without making huge capital investments and by eclipsing the various risks associated with complex bio-molecule production, the large, medium, small or virtual biopharma companies are all increasingly adopting the trend of outsourcing so as to meet the accelerated biopharmaceutical development and production demand effectively.
The biologics outsourcing global market has been segmented based on the developmental phase, product, end users and geography. Based on the phase, biologics outsourcing global market segmented into discovery, pre-clinical, clinical and commercial phases of biologics development. Among these, Commercial Phase outsourcing commanded the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030.
The increased therapeutic value of biologics and huge potential of biologics outsourcing global market has resulted in biopharma companies focusing on new partnerships and collaborations with CDMOs. For instance, in October 2021, Enzolytics (ENZC), a drug development company and Samsung Biologics, a CDMO have signed a strategic CDMO partnership to commercializing multiple proprietary therapeutics to treat debilitating infectious diseases.
The CDMOs and CROs are expanding their outsourcing capabilities either by launching new advanced services or collaborating with other biotechnology companies to add advanced capabilities. For instance, in December 2021, Curia launched messenger RNA (mRNA) services, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for full-scale sterile fill-finish services.
Currently, traditional biologics modalities such as monoclonal antibodies, recombinant proteins and vaccines are dominating the biologics market. However, in recent years emerging advanced biologics modalities such as gene therapy, cell therapy, antibody drug conjugates, RNA therapy, m-RNA vaccines and others are gaining more importance due to their potential therapeutic abilities in treating non-infectious diseases and infectious diseases.
As these advanced modalities are gaining importance, biologics CDMO are giving more attention to gain extra capabilities in CGT service offerings to tap the potential market. Some of the CDMO are following in-organic strategies like acquisition to provide end-to-end gene and cell therapy services. For instance, in March 2021, Charles River Laboratories International, Inc acquired Cognate BioServices, Inc, a premier, cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies, as well as for production of plasmid DNA and other inputs in the CDMO value chain. Some of the CDMO are combing their capabilities to provide end-end to CGT services.
Market Dynamics
Drivers and Opportunities
Increasing Trend of Outsourcing
Advanced Bioprocessing Capabilities of Bioservice Providers
Emergence of Next Generation Biologics
Escalating Approvals and Uptake of Biosimilars
Increasing Approvals and Adoption of Biologics
Increasing R&D Expenditures
Increasing Prevalence of Chronic, Communicable and Autoimmune Diseases
Development of Personalized and Orphan Indication Therapies
Restraints and Threats
Increasing Focus on In-House Biologics Manufacturing
Huge Capital Investments for Capacity and Capability Development
Compliance with Stringent Regulatory Guidelines
Concerns About IP Protection
Competition and Trend of Outsourcing of Low Volume Biologics
Key Topics Covered:
1 Biologics Outsourcing Global Market
2 Market Analysis
3 Biologics Outsourcing Global Market, Market Analysis
4 Biologics Outsourcing Global Market - Biomanufacturing
5 Biologics Outsourcing Global Market - Cell Line Development
6 Company Profiles
Companies Mentioned
Abbvie Inc.
Agc Inc.
Avid Bioservices, Inc.
Boehringer Ingelheim International GmbH
Catalent Inc.
Charles River Laboratories
Curia
Emergent Biosolutions Inc.
Eurofins Scientific S.E.
Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnol0Gies)
Genscript Biotech Corporation
Jsr Corporation
Laboratory Corp of America Holdings
Lonza Group Ltd.
Merck KGaA
National Resilience, Inc.
Rentschler Biopharma SE
Samsung Biologics Co. Ltd.
Thermo Fisher Scientific Inc.
Wuxi Apptec Co. Ltd.
Wuxi Biologics (Cayman) Inc.
For more information about this report visit https://www.researchandmarkets.com/r/6ypl27
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
I do not see the analogy here Jeff - but hey I want ENZC to succeed.
Right on BonnieMac!!!!
Bonnie, here is my gmail if you want I can email it to you- just email me. jmach1095@gmail.com . that goes out to all if you want to hear that song
I know I said I would not post until Fins came out.
"If You Mess with America (You'll Have to Mess with Me).mp3." A friend from High School wrote, produced this song last year. Shoot I cannot post the MP3 file on ENZC for all to hear it. I agree Bonnie.
No more post for me until FINS come out!!!!
No, the Fins are not announced yet-soon it will be out- it is Monday a new week and yes it is the week Timing101 , Ralphie and some others on the sidelines have mentioned that the FINS should be out this week or by end of month? Go figure .
I agree, same here I do not pray for money - just people's health and well being as well as my own. If you pray for money you are missing the point of prayer - jmo.
Timing101, how many devices you have bugged in Charles office? LOL - Great post-thanks for the DD. Ralphie Jones agrees it is happening and there is no going backwards from this here it is all forward movement. JMO and Ralphie Jones's
It ran to .94 cause it was pumped - where were you? I sold at the high bought back at when it dropped and bought more when it was below .06 cents recently - yes it was pumped on what it will become as it will become the ENZC we all hope for soon. Remember GF and others on twitter/facebook and the pandemic it wa sthe perfect storm for a run.- those guys were all over it. It was a snowball effect back then with just hope and wishes - now it will be for real and I believe the good Doctor Chandra and his team will be nominated for the nobel prize in the future. JMO.